- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07946926
Adaptation of Facilitated Access to Mutual Aid for Community Alcohol and Drug Services (FAMA)
Adaptation of a Facilitated Access to Mutual Aid (FAMA) Intervention for Adults Accessing Community Alcohol and Drug Services in England.
Alcohol and other drug (AOD) use disorders are associated with a range of adverse outcomes. Relapse following AOD treatment is common. Attendance at Mutual Aid Groups (MAGs) is associated with improved health outcomes and reduced healthcare utilisation costs. National guidance recommends that clinical staff promote MAG attendance, but few patients are referred to, or attend, MAGs. An intensive referral intervention, developed in the United States of America has been shown to increase engagement with MAGs. The aim of this National Institute for Health Research (NIHR)-funded study is to adapt and test a Facilitated Access to Mutual Aid (FAMA) intervention and staff training for delivery in community AOD services in England.
Phase one of this study consists of qualitative focus groups conducted with staff of community AOD services and adults receiving AOD treatment. Eight focus groups will explore participants' views of MAGs and the existing American FAMA intervention. The FAMA intervention will then be adapted and staff training developed, based on the focus group findings and input from patient and public involvement and engagement (PPIE) groups.
Phase two of this study consists of testing the adapted FAMA intervention. Staff in one community AOD service will receive the newly developed FAMA training. They will deliver FAMA to people who are currently receiving AOD treatment service. Each session will be recorded and the fidelity of intervention delivery will be assessed by the research team using a checklist. Staff and patient feedback will be collected using brief questionnaires in informal feedback sessions. The FAMA intervention will be refined and delivered again with another round of feedback being collected. A final version of the FAMA intervention will then be agreed by the research team and PPIE groups.
Descripción general del estudio
Estado
Condiciones
Tipo de estudio
Inscripción (Estimado)
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Adults aged 18+ years who are accessing AOD treatment and staff, aged 18+ years who are working in paid client facing role in an AOD treatment service.
Descripción
Phase one (staff) inclusion criteria:
- Aged 18+ years
- Currently working in a paid client facing role in an AOD treatment service
Phase one (people accessing AOD treatment) inclusion criteria:
- Aged 18+ years
- Currently receiving treatment from an AOD treatment service
Phase two (staff) inclusion criteria:
- Aged 18+ years
- Currently working as a keyworker or recover worker in an AOD treatment service
Phase two (people accessing AOD treatment) inclusion criteria:
- Aged 18+ years
- Currently receiving treatment from an AOD treatment service
- On a participating staff member's caseload
- Not attending MAGs.
Exclusion Criteria:
- N/A
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: OTHER
- Perspectivas temporales: CROSS_SECTIONAL
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Qualitative focus groups
Periodo de tiempo: Focus groups will last approximately 90 minutes
|
Qualitative focus groups |
Focus groups will last approximately 90 minutes
|
|
Acceptability of Intervention measure (AIM) adapted for FAMA
Periodo de tiempo: Maximum 10 weeks from enrolment in the study
|
Measures whether participants find FAMA to be acceptable |
Maximum 10 weeks from enrolment in the study
|
|
Feasibility of Intervention (FIM) adapted for FAMA
Periodo de tiempo: Maximum 10 weeks from enrolment in the study
|
Measures whether participants find FAMA to be feasible |
Maximum 10 weeks from enrolment in the study
|
|
Appropriateness Measure (IAM) adapted for FAMA
Periodo de tiempo: Maximum 10 weeks from enrolment in the study
|
Measures whether participants find FAMA to be appropriate |
Maximum 10 weeks from enrolment in the study
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- IRAS 370125
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .